Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycoprotein B (human cytomegalovirus) (gB)
- Target
- gB
- Molecular classification
- Viral Fusion Protein, Glycoprotein
01
Overview
Glycoprotein B (gB) is a highly conserved, essential envelope protein of human cytomegalovirus (HCMV). It functions as the primary fusogen for HCMV, mediating virus attachment and membrane fusion with host cells, as well as cell-to-cell spread. It is a target for vaccine and therapeutic antibody development.
02
Mechanism of action
Viral entry inhibition via fusion interference
03
Biological functions
Membrane fusionHost cell entryCell-to-cell spread
04
Disease associations
InfectionHCMV-related diseaseCongenital cytomegalovirus infection
05
Safety considerations
Elicits mostly non-neutralizing antibodiesPartial vaccine efficacy when used alone
Beyond the preview
Go deeper on Glycoprotein B (human cytomegalovirus) (gB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycoprotein B (human cytomegalovirus) (gB).